Bruker (NASDAQ:BRKR) Trading Up 7.7% – Should You Buy?

Bruker Corporation (NASDAQ:BRKR)’s share price rose 7.7% during trading on Tuesday . The stock traded as high as $60.63 and last traded at $60.4980. 396,004 shares changed hands during trading, a decline of 83% from the average session volume of 2,379,252 shares. The stock had previously closed at $56.17.

Analyst Ratings Changes

A number of research analysts have recently commented on BRKR shares. Wall Street Zen raised Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. TD Cowen reissued a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Wolfe Research started coverage on shares of Bruker in a report on Monday, June 1st. They issued a “peer perform” rating on the stock. Finally, Barclays upped their price target on shares of Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $56.79.

Bruker Stock Up 5.2%

The firm has a 50 day moving average of $54.97 and a 200-day moving average of $45.94. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The stock has a market capitalization of $9.00 billion, a P/E ratio of -245.94, a price-to-earnings-growth ratio of 1.86 and a beta of 1.29.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The business had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.Bruker’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s payout ratio is presently -83.33%.

Institutional Investors Weigh In On Bruker

Large investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC bought a new position in shares of Bruker during the 4th quarter worth approximately $26,000. Allworth Financial LP boosted its stake in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares in the last quarter. Essential Partners LLC bought a new stake in shares of Bruker in the 1st quarter worth about $36,000. Parallel Advisors LLC increased its position in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in Bruker during the 4th quarter valued at about $50,000. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.